Cargando…

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions

The central nervous system (CNS) is an immune-privileged compartment that is separated from the circulating blood and the peripheral organs by the blood–brain and the blood–cerebrospinal fluid (CSF) barriers. Transmigration of lymphocyte subsets across these barriers and their activation/differentia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gross, Catharina C., Pawlitzki, Marc, Schulte-Mecklenbeck, Andreas, Rolfes, Leoni, Ruck, Tobias, Hundehege, Petra, Wiendl, Heinz, Herty, Michael, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139518/ https://www.ncbi.nlm.nih.gov/pubmed/32192056 http://dx.doi.org/10.3390/ijms21062046

Ejemplares similares

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry
por: Heming, Michael, et al.
Publicado: (2023)

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis
por: Thomas, Christian, et al.
Publicado: (2018)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Classification of neurological diseases using multi-dimensional CSF analysis
por: Gross, Catharina C, et al.
Publicado: (2021)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Trafficking of lymphocytes into the CNS
por: Schwab, Nicholas, et al.
Publicado: (2015)

Natural Killer Cells Are Present in Rag1(−/−) Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke
por: Rolfes, Leoni, et al.
Publicado: (2021)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer
por: Dik, Andre, et al.
Publicado: (2018)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection
por: Pawlitzki, Marc, et al.
Publicado: (2021)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

Primary Angiitis of the CNS: A Systematic Review and Meta-analysis
por: Beuker, Carolin, et al.
Publicado: (2021)

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid
por: Grauer, Oliver M, et al.
Publicado: (2015)

Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System
por: Ruland, Tillmann, et al.
Publicado: (2018)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab
por: Strippel, Christine, et al.
Publicado: (2017)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5e6d61pt69c0pi3msb0qvr49f0